Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Book Release
  • Business
  • Financial
ncarol.com

The Patient Activation Measure® (PAM®) Assessment to be Incorporated into Select CMS Alternative Payment Models
ncarol.com/10026843

Trending...
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
Insignia Health
APM Model Awardees to Utilize PAM to Measure Performance
and Strengthen Patient Support

PORTLAND, Ore. - ncarol.com -- Insignia Health has been awarded a contract with the Centers for Medicare and Medicaid Services (CMS) to incorporate the Patient Activation Measure® (PAM®), plus a host of integrated solutions and services, to support up to five million beneficiaries.

As authorized by the Affordable Care Act, the Center for Medicare Medicaid Innovation (CMMI) develops Alternative Payment Models (APMs) aimed at achieving better individual healthcare, improved population health, and lower costs through improvements in care delivery across the United States.

To help advance its mission, CMMI has selected the Patient Activation Measure from Insignia Health to support up to five APMs with strategies to reduce cost and improve health outcomes.  Participating models will utilize PAM to measure a patient's ability to manage their health and healthcare, and to assess change over time.

More on ncarol.com
  • Detroit Roots, Film Scores and Python Shape KayeDinero's Asheville Sound
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off

Endorsed by the National Quality Forum (NQF) as a performance measure, PAM is also used to guide resource allocation and patient support based upon a patient's self-management ability or activation level.  Patients with lower activation struggle with self-management and utilize significantly more care when compared to patients with higher activation, including higher rates of emergency department visits, hospital readmissions, and use of ambulatory care sensitive (ACS) services.

"We are excited to be working with CMS at the forefront of value-based innovation to achieve improved health outcomes through the gains in self-management that we know patients can achieve," said Chris Delaney, CEO of Insignia Health.  "Measuring patient activation with PAM has proven to be a key vital sign backed by more than a decade of evidence showing that patients low in activation, when supported appropriately, realize the greatest gains in activation and improved health outcomes."

More on ncarol.com
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style
  • From Degrassi to Cass Tech: The Unexpected Influences Behind Asheville's KayeDinero
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
  • KayeDinero Takes "Appalachia" Above the Blue Ridge With New Aerial Music Visual
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes

About Insignia Health: Insignia Health is the global provider of PAM-based solutions that strengthen the identification of prospective health risk, and guide improved resource allocation and patient support.  The Patient Activation Measure® (PAM®) is a predictive powerhouse backed by over 15 years of health activation research and insight gained from supporting health systems, hospitals, insurers, life science companies and government health agencies around the world. The company's products and services help organizations better identify patients at risk for poor health outcomes and then tailor care programs and support based upon a patient's level of activation. Insignia Health is headquartered in Portland, Oregon. Visit www.insigniahealth.com to learn more.

Contact
Jim Honish
***@insigniahealth.com


Source: Insignia Health
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Google AI Says KayeDinero Isn't the Greatest Female Producer. She Asks: Who Decides?
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • From Michael Jackson to Drake: The Artists Who Shaped KayeDinero's Sound
  • L-Tron to Attend the 2026 NC, GA, TN, SC Joint Regional IAI Conference
  • "Kulture Metrics" Isn't Just an Album Title: KayeDinero Connects Music, Markets and Code
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pipeline Developer Isn't Just a Song: KayeDinero Builds Software, Markets and Music
  • Who Is KayeDinero? The Asheville Artist Also Builds Software and Trading Systems
  • Leaping Cat Creative Takes Shape Around the Problems Nobody Quite Owns
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
  • As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
  • Why Did KayeDinero Put Haywood Road Into a Song?
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 160
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 157
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 140
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 133
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 123
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 123
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 122
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 121
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies - 115
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 112

Similar on ncarol.com

  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • FOCUS Names Mark Phillips Senior Vice President of Business Development
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • L-Tron to Attend the 2026 NC, GA, TN, SC Joint Regional IAI Conference
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute